dasiglucagon vs Nasal Glucagon

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Severe Hypoglycemia

Shared mechanism: Glucagon receptor (agonist) · full Severe Hypoglycemia pipeline

dasiglucagon · Zegalogue

Rights held by Zealand Pharma and partners; US product discontinued

Approved in Severe Hypoglycemiapeptide
Partial signal

NCT03895697 · Phase 3 · completed

The trial randomized 92 participants and masked participants, care providers, investigators, and outcome assessors while comparing two dasiglucagon batches in a crossover design. Its primary measure was a physiological glucose-recovery endpoint rather than a hard clinical outcome, and no primary endpoint result is posted.

Reported efficacy

Time to Plasma Glucose Recovery (0-45 minutes after dosing): Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) (met)

Result source: NCT03378635

Nasal Glucagon · Baqsimi

Marketed by Amphastar Pharmaceuticals, Inc. and partners

Approved in Severe Hypoglycemiapeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Severe Hypoglycemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dasiglucagon
Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) NCT03378635 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Time to Plasma Glucose Recovery. (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 35 minutes NCT03688711 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12) NCT03667053 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nasal Glucagon

Normoglycemia 75% (n=8) vs 83.3% (n=18) SC Glucagon @ 0.002976190476190476wk3 mg
responder rate · % of participants
NCT01556594 · Phase 2 · registry result, not featured evidence
show 2 more results
50% (n=18) vs 83.3% (n=18) SC Glucagon @ 0.002976190476190476wk2 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
25% (n=12) vs 83.3% (n=18) SC Glucagon @ 0.002976190476190476wk1 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
Available safety results

Nasal Glucagon

Dropout rate
—3 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
show 2 more results
—2 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—3 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
show 2 more results
—2 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
Serious AEs
0%3 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
show 2 more results
0%2 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01556594 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
3 mg
lacrimation increased 75%
pallor 25%
tremor 25%
NCT01556594 · Phase 2 · registry result, not featured evidence
show 2 more results
2 mg
lacrimation increased 50%
headache 33.3%
asthenia 27.8%
NCT01556594 · Phase 2 · registry result, not featured evidence
1 mg
hyperhidrosis 25%
asthenia 16.7%
catheter site bruise 16.7%
NCT01556594 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dasiglucagon's landscape · Nasal Glucagon's landscape